Cover Image

Second-Generation Long-Acting Injectable Antipsychotics and the Risk of Treatment Failure in a Population-Based Cohort

Introduction: Second-generation long-acting injectable antipsychotics (SG-LAIAs) may improve outcomes compared to other antipsychotics. Real-world studies using linked administrative databases play an important role in assessing the comparative effectiveness of antipsychotic medications.Methods: We...

Full description

Saved in:

Bibliographic Details
Main Authors:	Donica Janzen (Author), James M. Bolton (Author), Christine Leong (Author), I fan Kuo (Author), Silvia Alessi-Severini (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Moving towards Universal Coverage of Direct-Acting Antiviral Therapies for Hepatitis C Infection in Canada: An Environmental Scan of Canadian Provinces and International Jurisdictions
by: Samantha Myers, et al.
Published: (2018)

An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use
by: Amy M. VandenBerg, PharmD, BCPP
Published: (2022)

Comment on "An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use"
by: Still Daniel PharmD, BCPP, et al.
Published: (2023)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
by: John M. Kane, et al.
Published: (2023)

Response to comment on the recently published article "An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use"
by: VandenBerg Amy M. PharmD, BCPP
Published: (2023)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
by: Francisco José Toja-Camba, et al.
Published: (2021)

Comparison of long-acting injectable antipsychotics with oral antipsychotics and hospital readmission rates in pediatric patients
by: Danial Chowdhury, PharmD, et al.
Published: (2024)

Long-Acting Injectable Antipsychotics-A Review on Formulation and In Vitro Dissolution
by: Magdalena Markowicz-Piasecka, et al.
Published: (2023)

Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics
by: Shubhra Mace, et al.
Published: (2019)

Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics
by: David D. Kim, et al.
Published: (2021)

Assessment of oral overlap with antipsychotic long-acting injectables initiated in an inpatient setting
by: Tran Jennifer T. PharmD, et al.
Published: (2023)

Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?
by: Carol Paton, et al.
Published: (2022)

Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-acting injectable antipsychotics or oral antipsychotics
by: Ching-Hua Lin, et al.
Published: (2022)

Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies
by: Francesco Bartoli, et al.
Published: (2023)

Pharmacist Administration of Long-Acting Injectable Antipsychotics to Community-Dwelling Patients: A Scoping Review
by: Andrea L. Murphy, et al.
Published: (2023)

Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners
by: Shaina Schwartz, PharmD, BCPP, et al.
Published: (2023)

Treating Children with ASD: The Perspective of Caregivers
by: Noor Breik, et al.
Published: (2018)

Second-generation antipsychotic and diabetes mellitus in children and adolescents
by: Carlo Ripoli, et al.
Published: (2017)

Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
by: Giuseppe Caruso, et al.
Published: (2020)

Long-acting antipsychotic treatments: focus on women with schizophrenia
by: Sofia Brissos, et al.
Published: (2024)

Barriers to long‐acting injectable atypical antipsychotic use in Japan: Insights from a comparative psychiatrist survey
by: Yoshiyo Oguchi, et al.
Published: (2024)

Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an modelling study
by: James R. O'Neill, et al.
Published: (2023)

Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study
by: Cristiana Montemagni, et al.
Published: (2022)

Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data
by: Caballero Joshua PharmD, BCPP, FCCP, et al.
Published: (2023)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
by: Christopher Evernden, BSc, BScPharm, ACPR, et al.
Published: (2021)

Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review
by: Kunal Maini, et al.
Published: (2021)

Long‐acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID‐19 pandemic: A micro‐narrative review
by: Yoshiyo Oguchi, et al.
Published: (2024)

Rural ambulatory care pharmacists providing in-clinic and home visit services improve adherence to long-acting injectable antipsychotics
by: Heng "Helen" Chang, PharmD, BCPS, et al.
Published: (2024)

Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
by: Taro Kishi, et al.
Published: (2021)

Online industry resources can help ensure continuity of care for patients on long-acting injectable antipsychotics while traveling or relocating
by: Brown Geoffrey W PharmD, et al.
Published: (2023)

Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management
by: Krill RA, et al.
Published: (2014)

Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
by: Marjie L. Hard, et al.
Published: (2019)

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients
by: Siddhesh A Kamat, et al.
Published: (2015)

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
by: Solmi M, et al.
Published: (2017)

Efficacy and safety of long-acting injectable oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis
by: Giovanni Vita, et al.
Published: (2024)

Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments
by: Sebastiano Alfio Torrisi, et al.
Published: (2020)

Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations
by: Yifei Liu, et al.
Published: (2023)

Oral and long-acting injectable antipsychotic discontinuation and relationship to side effects in people with first episode psychosis: a longitudinal analysis of electronic health record data
by: Rashmi Patel, et al.
Published: (2023)

A narrative review of metabolic monitoring of adult prescribed second-generation antipsychotics for severe mental illness
by: Pooja Gopal Poojari, et al.
Published: (2022)

Ziprasidone, a second-generation antipsychotic, affects core clock gene mRNA expression in mice
by: Shunpei Moriya, et al.
Published: (2020)